The complex coincident nature of AD and non-AD comorbidities [45, 46, 62, 63] underlines the need for further research in individuals with discordant biomarker status before one suggests the prioritization of tau over Aβ biomarkers, as a standalone biomarker strategy. The gene discussed is MAPT; the disease is Alzheimer disease.